company background image
CYTH

Cyclo Therapeutics NasdaqCM:CYTH Stock Report

Last Price

US$2.20

Market Cap

US$18.5m

7D

-2.7%

1Y

-78.5%

Updated

29 Jun, 2022

Data

Company Financials +
CYTH fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health4/6
Dividends0/6

CYTH Stock Overview

Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases.

Cyclo Therapeutics Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Cyclo Therapeutics
Historical stock prices
Current Share PriceUS$2.20
52 Week HighUS$10.40
52 Week LowUS$1.88
Beta-0.75
1 Month Change2.33%
3 Month Change-30.60%
1 Year Change-78.50%
3 Year Change-94.36%
5 Year Change-95.18%
Change since IPO-98.90%

Recent News & Updates

Shareholder Returns

CYTHUS BiotechsUS Market
7D-2.7%3.8%1.6%
1Y-78.5%-25.8%-20.8%

Return vs Industry: CYTH underperformed the US Biotechs industry which returned -26.1% over the past year.

Return vs Market: CYTH underperformed the US Market which returned -20.4% over the past year.

Price Volatility

Is CYTH's price volatile compared to industry and market?
CYTH volatility
CYTH Average Weekly Movement9.4%
Biotechs Industry Average Movement13.1%
Market Average Movement8.1%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.2%

Stable Share Price: CYTH is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: CYTH's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19909N. Finehttps://www.cyclotherapeutics.com

Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment of Alzheimer’s disease.

Cyclo Therapeutics Fundamentals Summary

How do Cyclo Therapeutics's earnings and revenue compare to its market cap?
CYTH fundamental statistics
Market CapUS$18.52m
Earnings (TTM)-US$13.02m
Revenue (TTM)US$1.42m

13.0x

P/S Ratio

-1.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CYTH income statement (TTM)
RevenueUS$1.42m
Cost of RevenueUS$151.31k
Gross ProfitUS$1.27m
Other ExpensesUS$14.29m
Earnings-US$13.02m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.55
Gross Margin89.36%
Net Profit Margin-915.39%
Debt/Equity Ratio0%

How did CYTH perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is CYTH undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CYTH?

Other financial metrics that can be useful for relative valuation.

CYTH key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue4.7x
Enterprise Value/EBITDA-0.5x
PEG Ration/a

Price to Sales Ratio vs Peers

How does CYTH's PS Ratio compare to its peers?

CYTH PS Ratio vs Peers
The above table shows the PS ratio for CYTH vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average9.7x
APVO Aptevo Therapeutics
1.4x11.5%US$17.7m
IKT Inhibikase Therapeutics
11.1xn/aUS$19.3m
SONN Sonnet BioTherapeutics Holdings
23x-122.1%US$16.3m
YMTX Yumanity Therapeutics
3.4xn/aUS$18.9m
CYTH Cyclo Therapeutics
13x67.2%US$18.5m

Price-To-Sales vs Peers: CYTH is expensive based on its Price-To-Sales Ratio (13x) compared to the peer average (9.7x).


Price to Earnings Ratio vs Industry

How does CYTH's PE Ratio compare vs other companies in the US Biotechs Industry?

Price-To-Sales vs Industry: CYTH is good value based on its Price-To-Sales Ratio (13x) compared to the US Biotechs industry average (13.4x)


Price to Sales Ratio vs Fair Ratio

What is CYTH's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CYTH PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio13x
Fair PS Ratio13.2x

Price-To-Sales vs Fair Ratio: CYTH is good value based on its Price-To-Sales Ratio (13x) compared to the estimated Fair Price-To-Sales Ratio (13.2x).


Share Price vs Fair Value

What is the Fair Price of CYTH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate CYTH's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate CYTH's fair value for valuation analysis.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CYTH's PEG Ratio to determine if it is good value.


Discover undervalued companies

Future Growth

How is Cyclo Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


25.4%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CYTH is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CYTH is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CYTH is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CYTH's revenue (67.2% per year) is forecast to grow faster than the US market (8.3% per year).

High Growth Revenue: CYTH's revenue (67.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if CYTH's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has Cyclo Therapeutics performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-29.7%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: CYTH is currently unprofitable.

Growing Profit Margin: CYTH is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: CYTH is unprofitable, and losses have increased over the past 5 years at a rate of 29.7% per year.

Accelerating Growth: Unable to compare CYTH's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CYTH is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).


Return on Equity

High ROE: CYTH has a negative Return on Equity (-99.8%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Cyclo Therapeutics's financial position?

Financial Health Score

4/6

Financial Health Score 4/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: CYTH's short term assets ($15.9M) exceed its short term liabilities ($2.9M).

Long Term Liabilities: CYTH has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: CYTH is debt free.

Reducing Debt: CYTH had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CYTH has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: CYTH has less than a year of cash runway if free cash flow continues to reduce at historical rates of 33.7% each year


Discover healthy companies

Dividend

What is Cyclo Therapeutics's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate CYTH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CYTH's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CYTH's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CYTH's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as CYTH has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

6.8yrs

Average management tenure


CEO

N. Fine (64 yo)

6.75yrs

Tenure

US$1,080,655

Compensation

Mr. N. Scott Fine has been Chief Executive Officer of Cyclo Therapeutics, Inc. (formerly known as CTD Holdings, Inc.) since September 14, 2015. Mr. Fine served as the Chairman of Cyclo Therapeutics, Inc. s...


CEO Compensation Analysis

Compensation vs Market: N.'s total compensation ($USD1.08M) is above average for companies of similar size in the US market ($USD759.63K).

Compensation vs Earnings: N.'s compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: CYTH's management team is seasoned and experienced (6.8 years average tenure).


Board Members

Experienced Board: CYTH's board of directors are considered experienced (7.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: CYTH insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 32.4%.


Top Shareholders

Company Information

Cyclo Therapeutics, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Cyclo Therapeutics, Inc.
  • Ticker: CYTH
  • Exchange: NasdaqCM
  • Founded: 1990
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$18.516m
  • Shares outstanding: 8.42m
  • Website: https://www.cyclotherapeutics.com

Number of Employees


Location

  • Cyclo Therapeutics, Inc.
  • 6714 NW 16th Street
  • Suite B
  • Gainesville
  • Florida
  • 32653
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/29 00:00
End of Day Share Price2022/06/29 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.